Literature DB >> 12557231

Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5' region of MEL1.

Phan Thi Xinh1, Nguyen Khanh Tri, Hiromasa Nagao, Hiroshi Nakazato, Fumitoshi Taketazu, Shin Fujisawa, Fumiharu Yagasaki, Ying Zhang Chen, Yasuhide Hayashi, Atsushi Toyoda, Masahira Hattori, Yoshiyuki Sakaki, Katsushi Tokunaga, Yuko Sato.   

Abstract

The recurrent translocation t(1;3)(p36;q21) is associated with myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) characterized by trilineage dysplasia, especially dysmegakaryopoiesis and a poor prognosis. Recently, the two genes involved in this translocation have been identified: the MEL1 gene at 1p36.3, and the RPN1 gene at 3q21. The breakpoint in RPN1 is centromeric to the breakpoint cluster region of the inv(3) abnormality. Because the MEL1 transcript is detected only in leukemic cells with t(1;3)(p36;q21), ectopic expression of MEL1 driven by RPN1 at 3q21 is thought to contribute to the pathogenesis of t(1;3)(p36;q21) leukemia. However, the precise breakpoint in the patients has not yet been identified. With fluorescence in situ hybridization analysis by use of BAC/PAC probes, we identified the breakpoint at 1p36.3 in three MDS/AML patients with t(1;3)(p36;q21): within the first intron of the MEL1 gene (one patient) or within a 29-kb region located in the 5' region of MEL1 (two other patients). We detected several sizes of MEL1 transcript in two patients including the first patient, although we have not yet clarified whether MEL1 transcripts were different among the patients and whether a truncated MEL1 transcript was expressed in the first patient. This patient showed an unusual clinical profile, repeating progression to overt leukemia and conversion to MDS three times during the 29-month survival period, which might be related to a different molecular mechanism in this patient. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557231     DOI: 10.1002/gcc.10176

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.

Authors:  Suzy Davies; Donghai Dai; Gavin Pickett; Kristina W Thiel; Victoria P Korovkina; Kimberly K Leslie
Journal:  Oncol Rep       Date:  2011-01-14       Impact factor: 3.906

2.  DNA Methylation in Babies Born to Nonsmoking Mothers Exposed to Secondhand Smoke during Pregnancy: An Epigenome-Wide Association Study.

Authors:  Bernard F Fuemmeler; Mikhail G Dozmorov; Elizabeth K Do; Junfeng Jim Zhang; Carole Grenier; Zhiqing Huang; Rachel L Maguire; Scott H Kollins; Cathrine Hoyo; Susan K Murphy
Journal:  Environ Health Perspect       Date:  2021-05-19       Impact factor: 9.031

3.  The zinc finger SET domain gene Prdm14 is overexpressed in lymphoblastic lymphomas with retroviral insertions at Evi32.

Authors:  E J Dettman; Monica J Justice
Journal:  PLoS One       Date:  2008-11-27       Impact factor: 3.240

4.  Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Nicola Aceto; Virginie Remy; Stephane Pinson; Claude Houdayer; Christine Arnoulet; Danielle Sainty; Mohamed Bentires-Alj; Sylviane Olschwang; Norbert Vey; Marie-Joëlle Mozziconacci; Daniel Birnbaum; Max Chaffanet
Journal:  BMC Cancer       Date:  2008-10-16       Impact factor: 4.430

Review 5.  Multifaceted Role of PRDM Proteins in Human Cancer.

Authors:  Amelia Casamassimi; Monica Rienzo; Erika Di Zazzo; Anna Sorrentino; Donatella Fiore; Maria Chiara Proto; Bruno Moncharmont; Patrizia Gazzerro; Maurizio Bifulco; Ciro Abbondanza
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.